振德医疗(603301) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 991,564,852.44, representing a 2.87% increase compared to CNY 963,887,437.65 in the same period last year[4] - Net profit attributable to shareholders decreased by 30.19% to CNY 51,241,871.64 from CNY 73,397,631.01 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 36.34% to CNY 47,555,148.75 compared to CNY 74,696,045.21 in the previous year[4] - Basic and diluted earnings per share decreased by 32.14% to CNY 0.19 from CNY 0.28 year-on-year[4] - Net profit for Q1 2025 was ¥52,407,784.36, a decrease of 30.3% from ¥75,230,110.17 in Q1 2024[18] - Earnings per share for Q1 2025 were ¥0.19, down from ¥0.28 in Q1 2024[18] - The company reported a total comprehensive income of ¥74,364,364.64 for Q1 2025, compared to ¥112,931,841.28 in Q1 2024, a decrease of 34%[18] Cash Flow - The net cash flow from operating activities was negative at CNY -27,769,957.87, a significant decline of 205.60% from CNY 26,297,173.49 in the same period last year[4] - Cash inflow from operating activities for Q1 2025 was $1,196,695,032.81, an increase of 14.2% compared to $1,048,332,483.77 in Q1 2024[22] - The total cash inflow from operating activities was $1,196,695,032.81, while total cash outflow was $1,224,464,990.68, resulting in a net cash flow of -$27,769,957.87 for Q1 2025[22] - Cash outflow for purchasing goods and services was $717,154,156.32 in Q1 2025, up from $641,089,503.20 in Q1 2024, reflecting a 11.9% increase[22] - Cash inflow from financing activities decreased to $740,000,000.00 in Q1 2025 from $1,127,760,000.00 in Q1 2024, a decline of 34.3%[23] - The ending cash and cash equivalents balance for Q1 2025 was $922,246,634.03, a decrease of 41.2% from $1,569,377,047.93 in Q1 2024[23] - The company reported a cash outflow of $134,087,464.68 for taxes in Q1 2025, significantly higher than $64,463,864.95 in Q1 2024, indicating a 107.5% increase[22] Assets and Liabilities - Total assets increased by 7.36% to CNY 8,134,455,327.52 from CNY 7,576,854,384.35 at the end of the previous year[5] - Total liabilities increased to CNY 3,073,006,079.04, with short-term borrowings rising significantly to CNY 706,935,455.19 from CNY 266,715,241.50, marking an increase of approximately 164.0%[13] - The total assets of the company reached CNY 8,134,455,327.52, up from CNY 7,576,854,384.35, which is an increase of about 7.3%[13] - The company's non-current assets totaled CNY 5,061,449,248.48, compared to CNY 4,927,035,342.48, reflecting a growth of approximately 2.7%[13] - Total liabilities increased to ¥2,163,686,458.58 in Q1 2025, compared to ¥1,680,456,463.01 in Q1 2024, reflecting a growth of 28.7%[14] - Total equity rose to ¥5,970,768,868.94 in Q1 2025, compared to ¥5,896,397,921.34 in Q1 2024, marking an increase of 1.3%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,690[9] - The company has not reported any significant changes in shareholder structure or participation in margin trading activities during the reporting period[11] Costs and Expenses - The company experienced increased costs due to exchange rate fluctuations, higher operational expenses from new overseas production facilities, and increased R&D investments[7] - Total operating costs for Q1 2025 were ¥932,157,374.02, up 7.1% from ¥870,157,936.80 in Q1 2024[17] - Research and development expenses for Q1 2025 were ¥33,484,212.15, up from ¥29,493,825.79 in Q1 2024, indicating a growth of 13.5%[17] Other Financial Metrics - The weighted average return on equity decreased by 0.46 percentage points to 0.90% from 1.36% year-on-year[4] - The company reported a total non-recurring gains and losses of CNY 3,686,722.89 for the period[7] - Other comprehensive income after tax for Q1 2025 was ¥21,956,580.28, down from ¥37,701,731.11 in Q1 2024[18] - Long-term borrowings increased to ¥385,900,927.80 in Q1 2025 from ¥283,106,001.32 in Q1 2024, reflecting a growth of 36.4%[14] - The company experienced a negative impact of -$678,206.74 from exchange rate fluctuations in Q1 2025, contrasting with a positive impact of $11,066,285.10 in Q1 2024[23]